摘要
目的探讨利巴韦林在病毒感染治疗中的应用效果及其安全性。通过对比分析,评估利巴韦林对特定病毒感染患者的疗效和安全性,为临床治疗提供科学依据。方法选取2024年2月至2025年2月期间确诊为病毒感染的180例患者作为研究对象,随机分为两组,每组90例。研究组接受标准抗病毒治疗联合利巴韦林治疗,对照组仅接受标准抗病毒治疗。观察指标包括退热时间、症状缓解时间、住院天数、病毒转阴率及不良反应发生率。所有数据采用SPSS 26.0软件进行统计学处理,P<0.05认为差异具有统计学意义。结果研究组的平均退热时间为3.2天,而对照组为4.8天;症状缓解时间分别为5.7天和7.9天;住院天数分别为8.3天和11.2天;病毒转阴率方面,研究组达到87%,对照组则为72%。在不良反应发生率上,研究组记录到轻微不适者占总人数的8%,对照组中这一比例为5%。尽管研究组在不良反应发生率上略高于对照组,但未见严重不良事件报告,且上述各项主要观察指标均显示出显著性差异(P<0.05)。结论利巴韦林应用于病毒感染治疗中表现出良好的疗效和可接受的安全性。相较于单纯的标准抗病毒治疗,联合使用利巴韦林能够有效缩短患者的退热时间、症状缓解时间和住院天数,并提高病毒转阴率。虽然轻微不良反应的发生率略有上升,但这并未影响总体治疗效果。因此,在临床实践中合理使用利巴韦林可以作为一种有效的辅助治疗方法,以改善病毒感染患者的预后。然而,对于其长期安全性和更广泛的适用性仍需进一步的研究加以验证。
Objective To explore the application effect and safety of ribavirin in the treatment of viral infections.By comparative analysis,evaluate the efficacy and safety of ribavirin in patients with specific viral infections,and provide scientific basis for clinical treatment.Method 180 patients diagnosed with viral infections between February 2024 and February 2025 were selected as the study subjects and randomly divided into two groups,with 90 cases in each group.The research group received standard antiviral treatment combined with ribavirin treatment,while the control group only received standard antiviral treatment.Observation indicators include fever reduction time,symptom relief time,length of hospital stay,virus seroconversion rate,and incidence of adverse reactions.All data were statistically processed using SPSS 26.0 software,and P<0.05 was considered statistically significant.Result The average fever reduction time of the research group was 3.2 days,while that of the control group was 4.8 days;The symptom relief time was 5.7 days and 7.9 days,respectively;The hospitalization days were 8.3 days and 11.2 days,respectively;In terms of virus conversion rate,the research group reached 87%,while the control group was 72%.In terms of the incidence of adverse reactions,the study group recorded that 8%of the total population had mild discomfort,while in the control group,this proportion was 5%.Although the incidence of adverse reactions in the study group was slightly higher than that in the control group,there were no reports of serious adverse events,and the main observation indicators mentioned above showed significant differences(P<0.05).Conclusion Ribavirin has shown good efficacy and acceptable safety in the treatment of viral infections.Compared to standard antiviral treatment alone,the combined use of ribavirin can effectively shorten the patient's fever reduction time,symptom relief time,and hospital stay,and improve the virus conversion rate.Although the incidence of mild adverse reactions has slightly increased,it has not affected the overall treatment outcome.Therefore,the rational use of ribavirin in clinical practice can serve as an effective adjuvant therapy to improve the prognosis of patients with viral infections.However,further research is needed to verify its long-term safety and wider applicability.
作者
宗爽
Shuang Zong(Dingxing County Hospital,Baoding,Hebei 072650)
出处
《医学研究前沿》
2025年第6期51-53,共3页
Frontiers of Medical Research
关键词
利巴韦林
病毒感染
治疗效果
安全性
退热时间
ribavirin
viral infection
treatment efficacy
safety
fever reduction time
